Page 26 - Cancer Update Spring 2019 Vol. 8 Issue 1

24
BAYLOR CHARLES A. SAMMONS CANCER CENTER
PEPTIDE RECEPTOR RADIONUCLIDE THERAPY
Peptide receptor radionuclide therapy (PRRT) for neuroendocrine cancer (NET) takes advantage of the observation that somatostatin receptors are expressed on 50 to 80% of NETs, especially those originating in the gastrointestinal system. The goal of PRRT is to target the somatostatin receptor-containing tumor cells with a cytotoxic dose of radiation while sparing the nearby nontumor tissue.
Somatostatin, also known as growth hormone-inhibiting hormone, is a peptide derived from the SST gene that binds to any of five G protein-coupled transmembrane receptors (SSTR1-5) as part of a neuroendocrine feedback loop. Because somatostatin receptor activation reduces hormone secretion, this receptor can be used as a drug target to help control the symptoms of neuroendocrine cancer and improve quality of life. Therefore, somatostatin analogs such as octreotide (Sandostatin) and lanreotide (Somatuline) were developed as long-acting alternatives to somatostatin for therapeutic use.
6 / Innovative Immuno-Oncology Clinical 11 / A Multidisciplinary Approach 23 / Neuroendocrine Cancer in the Skin: A Publication for Baylor Scott & White Health’s Oncology Program Trial Using Natural Killer Cells to Neuroendocrine Cancer Merkel Cell Carcinoma